Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway

Abstract

Endocrine resistance is a major challenge in the management of estrogen receptor (ER)-positive breast cancers. Although multiple mechanisms leading to endocrine resistance have been proposed, the poor outcome of patients developing resistance to endocrine therapy warrants additional studies. Here we show that noncanonical Hedgehog (Hh) signaling is an alternative growth promoting mechanism that is activated in tamoxifen-resistant tumors. Importantly, phosphoinositide 3-kinase inhibitor/protein kinase B (PI3K/AKT) pathway plays a key role in regulating Hh signaling by protecting key components of this pathway from proteasomal degradation. The levels of Hh-signaling molecules SMO and GLI1 and the targets were significantly elevated in tamoxifen-resistant MCF-7 cells and T47D cells. Serial passage of the resistant cells in mice resulted in aggressive tumors that metastasized to distant organs with concurrent increases in Hh marker expression and epithelial mesenchymal transition. RNAi-mediated depletion of SMO or GLI1 in the resistant cells resulted in reduced proliferation, clonogenic survival and delayed G1–S transition. Notably, treatment of resistant cells with PI3K inhibitors decreased SMO and GLI1 protein levels and activity that was rescued upon blocking GSK3β and proteasomal degradation. Furthermore, treatment of tamoxifen-resistant xenografts with anti-Hh compound GDC-0449 blocked tumor growth in mice. Importantly, high GLI1 expression correlated inversely with disease-free and overall survival in a cohort of 315 patients with breast cancer. In summary, our results describe a signaling event linking PI3K/AKT pathway with Hh signaling that promotes tamoxifen resistance. Targeting Hh pathway alone or in combination with PI3K/AKT pathway could therefore be a novel therapeutic option in treating endocrine-resistant breast cancer.

Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells

“…A number of developmental signaling pathways, including Notch, PI3K/Akt, Wnt/β-catenin, Hedgehog and p53, [49][50][51] have been shown to have central roles in mammary tumorigenesis and stem cell biology. Activation of the PI3K/ Akt pathway has emerged as a central feature of EMT.…”

Targeting cancer stem cells by using the nanoparticles

“…140 The Hh signaling cascade is initiated by Hh binding to the 12-transmembrane receptor Patched 1, which relieves its inhibition on Smoothened (Smo), culminating in the nuclear localization of DNA-binding Gli transcription factors in target cells. 141 Several research groups reported that Hh signaling is aberrantly activated in various cancer types, including colon, 142 brain, 143 and breast, 144 liver, 145 lung, 146 and ovarian 147 cancer. Therefore, targeting Hh signaling pathway may provide an effective therapeutic approach in the treatment of various cancers.…”

A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity

“…Menin recruits PRMT5 to the GLI1 promoter to lay down the H4R3me2 repressive mark in a Hedgehog signalingindependent manner 42 and a recently identified noncoding RNA induces H3K27me3 at the GLI1 promoter, thereby reducing RNA polymerase II recruitment. 43 GLI1 has frequently been implicated in cancer cell therapy resistance through decreased chemotherapy and radiotherapy responsiveness [44][45][46][47][48] and increased expression of cell surface drug transporters. [49][50][51] Recently, GLI1 was shown to drive resistance of AML cells to ribavirin and cytarabine through UGT1A-dependent glucuronidation of the compounds and inhibition of GLI1 with GANT61 restored sensitivity.…”